Company: TDBCP
Filing Date: 2025-04-03
Form Type: 424B3
Source: 0001140361-25-012065
Chunk: 16

Company: TORONTO DOMINION BANK
Filing Date: 2025-04-03
Form: 424B3
Chunk 16
---
 hedging transactions with the intent to realize a profit, regardless of whether the value of ARNs increases or decreases or whether the Redemption Amount on ARNs is more or less than the principal amount of ARNs. Any profit in connection with such hedging activities will be in addition to any other compensation that we, the agents and our or their respective affiliates receive for the sale of ARNs, which creates an additional incentive to sell ARNs to you. Our business activities and those of the agents relating to any Underlying Company or ARNs may create conflicts of interest with you.We, the agents and our or their respective affiliates, at the time of any offering of ARNs or in the future, may engage in business with any Underlying Company, including making loans to, equity investments in, or providing investment banking, asset management, or other services to such company, its affiliates, and its competitors. In connection with these activities, any of these entities may receive information about those companies that we will not divulge to you or other third parties. We, the agents and our or their respective affiliates have published, and in the future may publish, research reports on one or more of these companies. The agents may also publish research reports relating to our or our affiliates’ securities, including ARNs. This research is modified from time to time without notice and may express opinions or provide recommendations that are inconsistent with purchasing or holding your ARNs. Any of these activities may adversely affect the price of any Underlying Stock and, consequently, the market value of, and any amount payable on, your ARNs. None of us, the agents or our or their respective affiliates makes any representation to any purchasers of ARNs regarding any matters whatsoever relating to any Underlying Stock or any Underlying Company. Any purchaser of ARNs should undertake an independent investigation of any Underlying Stock and any Underlying Company to the extent that, in its judgment, is appropriate to make an informed decision regarding an investment in ARNs. The selection of an Underlying Stock does not reflect any investment recommendations from us, the agents or our or their respective affiliates. There may be potential conflicts of interest involving the calculation agent. We have the right to appoint and remove the calculation agent.We expect to appoint BofAS or one of its affiliates as the calculation agent or as joint calculation agent (along with us or one of our or their respective affiliates) for ARNs and, as such, we and/or BofAS, as joint calculation agents or calculation agent, will determine the Starting Value, the